FDA

Science

STAT reports that an FDA ‘breakthrough’ designation no longer automatically makes a new medical device eligible for extra Medicare payments.

Science

STAT reports that the therapy's benefit was smaller than in a similar analysis from a year earlier, though it continued to slow progression at four years.

Science

STAT reports that a late-stage study showed the pill helped improve symptoms, forming the basis for the FDA approval.